MLH1 and NaPi2b (SLC34A2) as Key Tumor Pathology Targets

1. Overview

This article focuses on the in-depth characterization of two critical tumor pathology targets: MLH1 and NaPi2b (SLC34A2), exploring their molecular functions, structural characteristics, clinical diagnostic value in oncology, and supporting research with high-performance antibodies from ANT BIO PTE. LTD.

2. Research Background

Precision tumor diagnosis relies on the identification and validation of specific molecular targets. DNA mismatch repair proteins and solute carrier family transporters have emerged as pivotal biomarkers for cancer screening, subtyping, prognosis evaluation, and therapeutic guidance. MLH1, a core mismatch repair protein, and NaPi2b (SLC34A2), a sodium-dependent phosphate transporter, exhibit distinct expression profiles and functional mechanisms across multiple tumor types, making them indispensable research objects in modern tumor pathology.

3. Research Strategy

The study systematically analyzed the structural domains, biological functions, and molecular mechanisms of MLH1 and NaPi2b. Immunohistochemical (IHC) techniques were employed to detect target protein expression in normal and tumor tissues, clarifying their diagnostic utility in hereditary and sporadic cancers. The research further validated the specificity and applicability of targeted antibodies for clinical sample detection.

4. Key Research Findings

4.1 MLH1: Core Regulator of DNA Mismatch Repair & Tumor Suppressor

MLH1 is a vital DNA repair enzyme that maintains genomic stability by correcting replication errors. It forms a functional heterodimer with PMS2 and participates in DNA damage response and apoptosis regulation.

Clinical Diagnostic Value: MLH1 deficiency is a hallmark of Lynch syndrome and hereditary colorectal cancer. Abnormal expression supports subtyping and prognosis assessment of sporadic colorectal cancer and endometrial cancer.

4.2 NaPi2b (SLC34A2): Phosphate Transporter & Tumor Diagnostic Marker

NaPi2b is a glycosylated transmembrane protein that mediates sodium-dependent phosphate uptake. It is widely distributed in healthy tissues and highly expressed in specific tumor types.

Clinical Diagnostic Value: Highly expressed in serous ovarian cancer and lung adenocarcinoma, serving as a auxiliary diagnostic and prognostic biomarker; expression in endometrial and thyroid cancers requires further investigation.

5. ANT BIO PTE. LTD. Products Empowering Research

The high-quality antibodies developed by ANT BIO PTE. LTD. provide reliable detection tools for this research, ensuring accurate and stable IHC staining results:

• MLH1 Recombinant Mouse mAb (SDT-R702, Cat# S0B2363): Specifically recognizes MLH1 protein, enabling clear distinction between positive and negative staining in clinical tissue samples, critical for Lynch syndrome and colorectal cancer diagnosis.
• NaPi2b/SLC34A2 Recombinant Rabbit mAb (SDT-1771-79, Cat# S0B2364): Exhibits high specificity and sensitivity, ideal for IHC detection of ovarian and lung adenocarcinoma samples.

IHC shows positive staining in paraffin-embedded human colon

IHC shows positive staining in paraffin-embedded human testis

IHC shows negative staining in paraffin-embedded human colon cancer

IHC shows negative staining in paraffin-embedded human pancreatic cancer

6. ANT BIO PTE. LTD. Related Product Portfolio